Condiciones de salud que comino negro puede ayudar a apoyar.
Clinical studies and reviews confirm N. sativa has gastroprotective and GI symptom-relieving effects. A PMC gastrointestinal review documents clinical evidence for relief of gastrointestinal disorders including functional dyspepsia; adverse effects including nausea and burning sensation noted at higher oil doses.
Clinical trials have examined topical and oral Nigella sativa for acne vulgaris. A 2022 systematic review and meta-analysis of RCTs covering multiple skin conditions including acne found an odds ratio of 4.59 (95% CI: 2.02–10.39) favouring N. sativa lotion over control. Antimicrobial and anti-inflammatory mechanisms are attributed primarily to thymoquinone.
Multiple clinical studies show N. sativa reduces symptoms of allergic rhinitis and related respiratory allergy. Reviews summarising clinical and experimental data confirm antihistaminic, immunomodulatory, and anti-inflammatory effects. Seed oil at 25–250 mg/kg for 15–30 days has alleviated allergic rhinitis symptoms in patients.
Multiple RCTs confirm N. sativa significantly increases total antioxidant capacity (TAC), superoxide dismutase (SOD), catalase (CAT), and glutathione while reducing MDA and TBARS in diabetic, haemodialysis, and other patient populations. The 2025 meta-analysis of 82 RCTs confirmed significant improvements in antioxidant markers.
Two placebo-controlled human trials found that N. sativa seed (500 mg once or twice daily for 4–9 weeks) reduced anxiety scores in healthy adolescents and elderly subjects. Mechanistic studies implicate antioxidant activity, GABAergic modulation, and thymoquinone's effects on neurotransmitter systems.
An RCT in rheumatoid arthritis patients (500 mg/day N. sativa oil for 8 weeks, double-blind placebo-controlled) showed significant reduction in inflammatory cytokines and oxidative stress markers. Multiple clinical reviews categorise rheumatoid arthritis among the inflammatory and autoimmune conditions with clinical evidence for N. sativa.
Multiple RCTs in adult asthma patients show N. sativa (1–2 g/day seeds or 1 g/day oil, 3–12 weeks) significantly improved asthma symptoms and pulmonary function. Clinical reviews and a 2021 updated comprehensive review confirm bronchodilatory and preventive effects in asthmatic patients.
Clinical trials confirm N. sativa's therapeutic activity in autoimmune-mediated conditions including rheumatoid arthritis, Behcet's disease, and inflammatory bowel disease. The clinical trial review (PMC5633670) explicitly identifies inflammatory and autoimmune disorders as a principal category of established clinical benefit.
A systematic review and meta-analysis of RCTs confirmed N. sativa significantly reduces systolic and diastolic blood pressure, with greater effect on SBP. N. sativa oil was more effective than seed powder. The 2025 meta-analysis of 82 RCTs confirmed significant improvements in SBP, DBP, and MAP.
Multiple RCTs and meta-analyses confirm N. sativa significantly lowers fasting blood glucose and HbA1c in type 2 diabetic patients. A one-year placebo-controlled trial (n=114) showed significant reductions in FBG and HbA1c alongside improved antioxidant status. A meta-analysis of 34 studies confirmed significant glycaemic improvement.
Black cumin (Nigella sativa) seed has clinical evidence for bronchial asthma, with multiple clinical trials and a dedicated literature review (PubMed 2018) confirming bronchodilatory and anti-inflammatory effects. A randomized controlled trial showed N. sativa supplementation improved lung function parameters and cytokine balance in partly controlled asthma patients. Its active constituent nigellone has demonstrated prophylactic effects in asthma and bronchitis.
A meta-analysis of 34 RCTs (2278 participants) found N. sativa significantly reduced total cholesterol (SMD: −1.78; p<0.001), LDL-C (SMD: −2.45; p<0.001), and TG while increasing HDL-C (SMD: +0.79; p<0.001). The 2025 meta-analysis of 82 RCTs confirmed these consistent lipid-lowering effects.
A meta-analysis of 7 RCTs across conditions including metabolic syndrome, NAFLD, obesity, ulcerative colitis, and rheumatoid arthritis showed N. sativa (1–3 g/day) significantly reduced serum CRP. A 2025 meta-analysis of 82 RCTs confirmed significant reductions in multiple inflammatory biomarkers including IL-6, TNF-α, and hs-CRP.
A placebo-controlled trial in healthy elderly men (≥55 years; 500 mg N. sativa twice daily for 9 weeks) showed significant improvements in memory, attention, and cognition. TQ prevents hippocampal pyramidal cell loss, inhibits acetylcholinesterase, and reduces neuroinflammation relevant to age-related cognitive decline.
Ulcerative colitis patients were included in a meta-analysis (7 RCTs) showing significant CRP reductions with N. sativa supplementation. Animal models confirm TQ's anti-colitic effects via NF-κB inhibition. The PMC GI review documents clinical and experimental evidence for N. sativa's effects on colitis.
Clinical and pharmacological studies show N. sativa and thymoquinone have antidepressant-relevant activity. Human pilot trials and RCT protocols report improvements in depression scores in haemodialysis and other patient populations. Mechanistic work shows modulation of serotonin, dopamine, and GABA pathways.
An RCT found N. sativa cream to be as effective as betamethasone in improving quality of life and reducing eczema severity, with both superior to eucerin alone. The 2022 systematic review of skin disease RCTs (14 RCTs, 732 participants) covered atopic dermatitis and eczema among other conditions.
Black cumin (Nigella sativa) has recognized traditional anticonvulsant use and has been tested in clinical trials. A double-blind crossover trial in children with refractory epilepsy found that thymoquinone (1 mg/kg, the main bioactive of Nigella sativa) significantly decreased mean seizure frequency versus placebo. Animal studies confirm anticonvulsant activity via opioid-mediated GABAergic enhancement.
A systematic review of 24 studies (including RCTs) found N. sativa improved sperm parameters, semen fluid, and testosterone in men. An RCT in infertile men with abnormal morphology demonstrated improved sperm count and motility. TQ promotes spermatogenesis and LH-stimulated testosterone production.
A 2025 meta-analysis of 82 RCTs found N. sativa supplementation significantly improved BMI, body fat percentage, waist circumference, weight, and waist-to-hip ratio. A 2025 PubMed study confirmed anti-adipogenic and lipid-lowering effects of N. sativa in human subjects.
Meta-analyses of RCTs confirm N. sativa significantly reduces blood pressure, LDL-cholesterol, total cholesterol, triglycerides, and inflammatory markers relevant to cardiovascular risk. A 2025 meta-analysis of 82 RCTs comprehensively confirmed improvements across cardiovascular risk factors including blood pressure, lipid profile, and inflammatory biomarkers.
Ulcerative colitis patients are included in a CRP meta-analysis showing significant anti-inflammatory effects with N. sativa. The PMC GI review documents experimental evidence for anti-colitic effects. Clinical and experimental evidence together support N. sativa's role in IBD-associated inflammation.
RCTs and meta-analyses confirm N. sativa reduces insulin resistance (HOMA-IR) and improves β-cell function. A one-year trial showed significantly lower insulin resistance and higher β-cell activity. Subgroup analysis found HOMA-IR decreased with >1 g/day N. sativa for >8 weeks.
Clinical trials and systematic reviews demonstrate N. sativa's nephroprotective effects, reducing creatinine, blood urea nitrogen, and progression of diabetic nephropathy. N. sativa also significantly reduced proteinuria in a randomised clinical trial in diabetic nephropathy patients.
A systematic review of 4 RCTs in NAFLD found N. sativa significantly reduced hepatic steatosis grade and serum liver enzymes (ALT, AST) in three of four trials. The 2025 meta-analysis of 82 RCTs confirmed significant improvements in ALT, AST, and ALP with N. sativa supplementation.
Clinical studies show N. sativa seed (1–2 g/day) or oil (1 g/day) for 3–12 weeks significantly improved asthma symptoms and pulmonary function in adult patients. Reviews covering clinical evidence confirm bronchodilatory and lung-protective effects in obstructive pulmonary disease and sulfur mustard-exposed individuals.
Two placebo-controlled clinical trials demonstrated that N. sativa seed (500 mg twice daily for 9 weeks in elderly men; 500 mg once daily for 4 weeks in adolescents) significantly improved memory, cognition, and attention. Mechanistic evidence includes acetylcholinesterase inhibition and antioxidant protection of hippocampal neurons.
Multiple RCTs and the 2025 meta-analysis of 82 RCTs confirm N. sativa improves all core components of metabolic syndrome—blood pressure, dyslipidaemia, hyperglycaemia, and obesity. An RCT in 60 metabolic syndrome patients showed NS oil with standard medications significantly reduced FBS, LDL, and total cholesterol.
An RCT evaluated three preparations of N. sativa for plaque psoriasis: topical 10% ointment, oral capsules (500 mg three times daily), and combination, over 12 weeks. The 2022 systematic review of skin RCTs covering psoriasis confirmed clinical benefit. A 2021 dermatology review covered N. sativa for plaque psoriasis.
A double-blind, placebo-controlled RCT in RA patients (1 g/day N. sativa oil for 8 weeks) demonstrated significant reductions in inflammatory cytokines and oxidative stress markers. Multiple meta-analyses including RA patients show significant CRP reduction with N. sativa supplementation.
Clinical studies show N. sativa seed (25–250 mg/kg/day) or oil (25 µl–0.5 ml/day) for 15–30 days alleviates symptoms of allergic rhinitis. Antihistaminic, immunomodulatory, and anti-inflammatory mechanisms have been identified in human studies.
Clinical and animal studies show N. sativa increases testosterone levels through LH-stimulated Leydig cell activity. A systematic review found N. sativa treatment improved sperm parameters and testosterone in men (p<0.05). TQ reinforces testosterone levels and testes tissue in multiple experimental models.
A 2024 meta-analysis of 34 RCTs (2278 participants) found N. sativa supplementation significantly reduced triglycerides (SMD: −1.27; 95% CI: −1.67 to −0.83; p<0.001). The 2025 meta-analysis of 82 RCTs further confirmed significant TG reduction.
N. sativa and TQ show gastroprotective effects in animal models, protecting gastric mucosa from ulcerative lesions. A clinical trial reported significant reduction in H. pylori positivity with N. sativa added to standard therapy. The PMC GI review documents gastroprotective and anti-ulcer evidence.
An RCT compared N. sativa oil with fish oil in vitiligo treatment. The 2022 systematic review of skin disease RCTs (14 RCTs) included vitiligo. The 2021 International Journal of Dermatology review covered N. sativa pharmacology for vitiligo.
A triple-blind RCT found topical N. sativa emulgel significantly improved episiotomy wound healing (REEDA score MD −0.79; p=0.001) and reduced pain versus placebo. Anti-inflammatory, antimicrobial, and antioxidant properties of TQ promote granulation tissue formation and collagen maturation.
N. sativa has a documented history of use in Islamic, Unani, and Middle Eastern traditional medicine for cold, fever, and respiratory infections. Its immunomodulatory, antimicrobial, and antiviral properties are supported by experimental evidence, though specific RCTs in cold/flu are limited.
Black cumin is listed in traditional Unani and Islamic medicine as a remedy for diarrhoea and gastrointestinal disturbances. PMC gastrointestinal reviews document anti-motility, antispasmodic, and anti-infective properties in experimental models relevant to diarrhoea, though dedicated clinical trials are lacking.
Black cumin is documented in Unani, Islamic, and Ayurvedic traditional medicine as a remedy for fever. Clinical reviews note that N. sativa supplementation decreases body temperature in allergic patients, and antipyretic-relevant anti-inflammatory mechanisms have been identified experimentally.
Black cumin is documented in Unani and Islamic traditional medicine as a remedy for gastric complaints including gastritis. The PMC GI review documents gastroprotective, anti-inflammatory, and antibacterial (including H. pylori activity) properties in experimental models relevant to gastritis.
Volver